|
1）Hanada R, Hanada T, Sigl V, et al. RANKL/RANK-beyond bones. J Mol Med (Berl). 2011; 89: 647-56
|
|
|
|
2）Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol. 2007; 7: 292-304
|
|
|
|
|
|
3）Schramek D, Leibbrandt A, Sigl V, et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature. 468: 98-102
|
|
|
|
|
|
4）Hanada R, Leibbrandt A, Hanada T, et al. Central control of fever and female body temperature by RANKL/RANK. Nature. 2009; 462: 505-9
|
|
|
|
|
|
5）Karsenty G, Wagner EF. Reaching a genetic and molecular understanding of skeletal develop-ment. Dev Cell. 2002; 2: 389-406
|
|
|
|
|
|
6）Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003; 423: 337-42
|
|
|
|
|
|
7）Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999; 397: 315-23
|
|
|
|
|
|
8）Dougall WC, Glaccum M, Charrier K, et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 1999; 13: 2412-24
|
|
|
|
|
|
9）Li J, Sarosi I, Yan XQ, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A. 2000; 97: 1566-71
|
|
|
|
|
|
10）Mizuno A, Amizuka N, Irie K, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun. 1998; 247: 610-5
|
|
|
|
|
|
11）Bucay N, Sarosi I, Dunstan CR, et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998; 12: 1260-8
|
|
|
|
|
|
12）Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999; 402: 304-9
|
|
|
|
|
|
13）Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009; 24: 153-61
|
|
|
|
|
|
14）Cohen SB, Dore RK, Lane NE, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 2008; 58: 1299-309
|
|
|
|
|
|
15）Arron JR, Choi Y. Bone versus immune system. Nature. 2000; 408: 535-6
|
|
|
|
|
|
16）Kim D, Mebius RE, MacMicking JD, et al. Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE. J Exp Med. 2000; 192: 1467-78
|
|
|
|
|
|
17）Rossi SW, Kim MY, Leibbrandt A, et al. RANK signals from CD4(+)3(-) inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla. J Exp Med. 2007; 204: 1267-72
|
|
|
|
|
|
18）Akiyama T, Shimo Y, Yanai H, et al. The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. Immunity. 2008; 29: 423-37
|
|
|
|
|
|
19）Hikosaka Y, Nitta T, Ohigashi I, et al. The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator. Immunity. 2008; 29: 438-50
|
|
|
|
|
|
20）Loser K, Mehling A, Loeser S, et al. Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med. 2006; 12: 1372-9
|
|
|
|
|
|
21）Knoop KA, Kumar N, Butler BR, et al. RANKL is necessary and sufficient to initiate development of antigen-sampling M cells in the intestinal epithelium. J Immunol. 2009; 183: 5738-47
|
|
|
|
|
|
22）Robinson GW, Karpf AB, Kratochwil K. Regulation of mammary gland development by tissue interaction. J Mammary Gland Biol Neoplasia. 1999; 4: 9-19
|
|
|
|
|
|
23）Robinson GW, Hennighausen L, Johnson PF. Side-branching in the mammary gland: the progesterone-Wnt connection. Genes Dev. 2000; 14: 889-94
|
|
|
|
|
|
24）Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science. 2000; 289: 1508-14
|
|
|
|
|
|
25）Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet. 2003; 4: 638-49
|
|
|
|
|
|
26）Srivastava S, Matsuda M, Hou Z, et al. Receptor activator of NF-kappaB ligand induction via Jak2 and Stat5a in mammary epithelial cells. J Biol Chem. 2003; 278: 46171-8
|
|
|
|
|
|
27）Fata JE, Kong YY, Li J, et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell. 2000; 103: 41-50
|
|
|
|
|
|
28）Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002; 2: 584-93
|
|
|
|
|
|
29）Southby J, Kissin MW, Danks JA, et al. Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer. Cancer Res. 1990; 50: 7710-6
|
|
|
|
|
|
30）Dougall WC, Chaisson M. The RANK/RANKL/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev. 2006; 25: 541-9
|
|
|
|
|
|
31）Jones DH, Nakashima T, Sanchez OH, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 2006; 440: 692-6
|
|
|
|
|
|
32）Luo JL, Tan W, Ricono JM, et al. Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature. 2007; 446: 690-4
|
|
|
|
|
|
33）Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphospho-nates. J Clin Oncol. 2009; 27: 1564-71
|
|
|
|
|
|
34）Asselin-Labat ML, Vaillant F, Sheridan JM, et al. Control of mammary stem cell function by steroid hormone signalling. Nature. 2010; 465: 798-802
|
|
|
|
|
|
35）Joshi PA, Jackson HW, Beristain AG, et al. Progesterone induces adult mammary stem cell expansion. Nature. 2010; 465: 803-7
|
|
|
|
|
|
36）Pike MC, Peters RK, Cozen W, et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst. 1997; 89: 1110-6
|
|
|
|
|
|
37）Gonzalez-Suarez E, Jacob AP, Jones J, et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcino-genesis. Nature. 2010; 468: 103-7
|
|
|
|
|
|
38）Nakagawa N, Kinosaki M, Yamaguchi K, et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclasto-genesis. Biochem Biophys Res Commun. 1998; 253: 395-400
|
|
|
|
|
|
39）Kartsogiannis V, Zhou H, Horwood NJ, et al. Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone. 1999; 25: 525-34
|
|
|
|
|
|
40）Morrison SF, Nakamura K, Madden CJ. Central control of thermogenesis in mammals. Exp Physiol. 2008; 93: 773-97
|
|
|
|
|
|
41）Ushikubi F, Segi E, Sugimoto Y, et al. Impaired febrile response in mice lacking the prosta-glandin E receptor subtype EP3. Nature. 1998; 395: 281-4
|
|
|
|
|